Palliative Care in Patients With Hematological Malignancies. We Have a Long Way to Go .

Background: Patients with hematological malignancies have significant and diverse palliative care needs but are not usually referred to specialist palliative care services in a timely manner, if at all. Objective: To identify the characteristics of patients with hematological malignancies referred to the palliative care service in a tertiary hospital in Mexico City. Patients: Retrospective study including consecutive patients with hematological malignancies referred to palliative care services at Mexico's National Cancer Institute. Results: Between 2011 and 2019, 5,017 patients with hematological malignancies were evaluated for first time at Mexico's National Cancer Institute. Of these, 9.1% (n = 457) were referred to palliative care. Most were male (53.4%), with a median age of 58 years. The most frequent diagnosis was non-Hodgkin lymphoma (54.9%). The primary indication for referral to palliative care was for cases wherein chemotherapy was no longer an option (disease refractory to treatment, 42.8%). The median time of referral to the palliative care service occurred 11.2 months after the first evaluation at the National Cancer Institute and death occurred on median 1.1 months after the first palliative care evaluation. Conclusion: Patients with hematological neoplasms are infrequently referred to Palliative Care at the Institute (9.1%). We found no clear referral criteria for Palliative Care referral and note that hematologists' optimism regarding a cure can delay referrals. Clearly, we have a long way to go in improving the number of patients referred, and we still saw frequent referrals near the end of life, but the high rate of outpatient referrals is encouraging.

High antibody level: an accurate serologic marker of viremia in asymptomatic people with hepatitis C infection.

BACKGROUND: The screening and diagnosis of hepatitis C virus (HCV) infection is initiated by testing for antibody to HCV (anti-HCV). A positive anti-HCV test in blood donors represents ongoing infection in only a variable proportion of individuals. Because a high anti-HCV level has been associated with viremia, a study was conducted to determine whether a high antibody level is an accurate serologic marker for viremia in asymptomatic anti-HCV-positive persons. STUDY DESIGN AND METHODS: In a diagnostic test study, we included 856 anti-HCV-positive blood donors in a blood bank at Guadalajara, Jalisco, Mexico, between 2002 and 2007. A third-generation amplified chemiluminescence assay (ChLIA HCV) was used to detect anti-HCV. A positive result of the qualitative nucleic acid test (HCV RNA) was considered the gold standard for viremia. RESULTS: By receiver operating characteristic analysis, the signal-to-cutoff (S/CO) ratio of 20 or more was chosen as optimal to identify viremia and so was defined as high anti-HCV level. There was a significant difference in the proportion of viremia between subjects with high antibody level and those with lower levels (93.7% vs. 1.8%, respectively; p < 0.001). A high antibody level showed a sensitivity for viremia of 96.6% (95% confidence interval [CI], 93.8%-98.1%), a specificity of 96.6% (95% CI, 94.8%-97.8%), and a likelihood ratio of 28.6 (95% CI, 18.4%-44.6%). CONCLUSION: A high antibody level (S/CO ratio >/=20 by ChLIA HCV) clearly divides the viremic from the nonviremic blood donors and functions as an accurate serologic marker to guide the use of routine HCV RNA testing to confirm hepatitis C infection.

Alpha-thalassemia in a selected population of Mexico

Objetivo. Identificar con técnicas de biología molecular, los de Ó-Thal en poblaciones hospitalarias seleccionadas. Métodos. Diez y ocho propositi con datos hematológicos y bioquímicos sugestivos de talasemia-Ó, seleccionados de 356 pacientes con probable hemoglobinopatía provenientes de cuatro hospitales de dos ciudades, se investigaron para seis alelos comunes de talasemia-Ó. Los estudios moleculares se realizaron por reacción en cadena de la polimerasa y digestión con enzimas de restricción específicas. Resultados. El alelo Ó se identificó en dos casos: el estudio familiar mostró el mismo alelo en la madre de ambos y se detectó además heterocigocidad para HbS en uno de ellos. El análisis con Apa I reveló en ambos pacientes la deleción clase I que es el alelo más comúnmente observado en el mundo. Este estudio mostró 2/356 (0.6 por ciento) de portadores Ó, una frecuencia baja comparada con la observada en otras poblaciones del mundo. La ausencia de los otros alelos sugiere que en México la talasemia-Ó es molecularmente tan heterogénea como la talasemia-ß